Navigation Links
Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO"

ROCKVILLE, Md., April 18, 2011 /PRNewswire-USNewswire/ -- Accelovance, a privately held clinical research company has been named the "Best Contract Research Organization (CRO)" for a third consecutive year. The World Vaccine Congress, held last week at the Gaylord National Hotel and Convention Center, Washington, D.C., hosted its annual Vaccine Industry Excellence (ViE) Awards to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the past 12 months.

"Recognition from our colleagues and clients at this level is truly an honor. I believe consistency in performance, value and partnership is what defines our company's success," said Stephen J. Trevisan, President and CEO.

The "Best CRO" category is designed to highlight the importance of contract research services within the vaccine industry; Accelovance has won the award three of the four years it has been a finalist. An international panel of judges evaluates category finalists on quality of work, range of services, strength of client relationships and performance.

"Quality and commitment are what define our organization," remarked Lee Barsky, Vice President of CRO Services. "It is equally rewarding to see how our diverse service offering helps Sponsors maintain growth despite challenging times in the industry."

Accelovance supports the business needs of biotech and small/mid pharma companies with cost-effective, flexible solutions that extend beyond traditional CRO services. Recently, the balanced perspective of study management and site operations positioned Accelovance to successfully rescue two Phase III therapeutic vaccine programs. Additionally, several Phase I vaccine studies in support of novel manufacturing or delivery methods are currently underway.

Headquartered in Rockville, Maryland, Accelovance has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. Accelovance offers wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company's website at

Media Contact:
Angie Wing
Phone: 240.238.4921

SOURCE Accelovance
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
2. DSM Biomedical Announces Continued Partnership with Spinelab
3. HSC Trial Shows Continued Significant Hair Growth at One Year Follow-up
4. Continued Demand Makes Monsanto and Agriculture Unique Investment Opportunities, Global Seeds and Traits Lead to Tell Investors
5. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
6. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
7. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
8. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
9. New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements
10. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
11. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
Breaking Biology Technology:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
Breaking Biology News(10 mins):